Abstract:According to the CDC (2017), more women than men have died from heart disease over the last 20–25 years. Yet, premenopausal women are protected against heart and cardiovascular disease (CVD) compared to age‐matched men. The cellular and molecular mechanisms underlying the transition from premenopause/perimenopause (CVD‐resistance) to postmenopause (CVD‐susceptible) in women is unknown and is the focus of this project. The critical barrier impeding translational progress is the lack of appropriate models to study menopause. Most studies have used surgical removal of ovaries (ovariectomy) as a model of menopause; yet this technique poorly recapitulates the natural, physiological transition to menopause that 90% of women experience. We overcome this barrier with administration of the chemical, 4‐vinylcyclohexene diepoxide (VCD), where we can mirror progressive ovarian failure and preserve the critical “perimenopause” transitional period, identical to humans. Using this model, we demonstrate that perimenopausal , like cycling (premenopausal) females, are protected from pathological angiotensin II (Ang II)‐induced cardiac remodeling, while menopausal females are not. Our novel finding that perimenopausal females remain protected, despite irregular cycling (prior to complete loss of estrogen), underscores the importance of studying the role of estrogen in CVD, across the transition from perimenopause to menopause. Multiple molecular, genetic and cellular mechanisms have been suggested to underlie protection against CVD in non‐cycling females, many of which put estrogen as the key mediator. We discovered that one of these pathways, the adenosine monophosphate‐activated kinase (AMPK) signaling axis, is activated by estrogen through direct binding of estrogen receptors to the α‐catalytic subunit of AMPK. Taken together with our published and preliminary data, we hypothesis that loss of AMPK signaling is responsible for the exacerbated pathological cardiac remodeling in menopause(see Fig.). To date, there are no studies that have tested the ability of AMPK activation to mitigate menopausal susceptibility to CVD. Aim Determine if AMPK is necessary and/or sufficient to impart protection against pathological cardiac remodeling in menopausal females. Rationale We discovered that AMPK signaling is severely disabled during menopause where females are more susceptible to CVD. Using the VCD mouse model of menopause, we will determine if protection against Ang II‐induced cardiac remodeling during menopause is AMPK‐dependent. Summary We plan to determine the cellular and molecular mechanisms in premenopausal and perimenopausal females that prevent associated cardiovascular morbidities; and determine the underlying shift that gives rise to increased susceptibility to CVD in menopausal females. Support or Funding Information IMSD: R25GM062584 BME CVTG (NIH‐T32): 5T32HL007955‐15AHA: 16GRNT31390006 This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

The impact of ovariectomy on cardiac excitation-contraction coupling is mediated through cAMP/PKA-dependent mechanisms

Impact of Estrogen Replacement on Ventricular Myocyte Contractile Function and Protein Kinase B/Akt Activation.

17-Β Estradiol Attenuates Ovariectomy-Induced Changes in Cardiomyocyte Contractile Function Via Activation of AMP-activated Protein Kinase.

Effect of ovariectomy on intracellular Ca2+ regulation in guinea pig cardiomyocytes

Influence of Ovariectomy on Ventricular Myocyte Contraction in Simulated Diabetes

Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS gene expression

O08 TESTOSTERONE CAN INDUCE CARDIAC HYPERTROPHY IN OVARIECTOMIZED SPONTANEOUSLY HYPERTENSIVE RATS THROUGH THE ACTIVATION OF THE mTORC2/Atg9a

Influence of Ovariectomy and 17Β-Estradiol Treatment on Insulin Sensitivity, Lipid Metabolism and Post-Ischemic Cardiac Function

Influence of Ovariectomy and Estrogen Replacement on Gene Expression Profile of Myocardium in Rats

TESTOSTERONE COULD INDUCE CARDIAC HYPERTROPHY IN OVARIECTOMIZED SHR THROUGH THE ACTIVATION OF THE MTORC2/ATG9A

Effects Of Oestrogen And Cimicifuga Racemosa On The Cardiac Noradrenaline Pathway Of Ovariectomized Rats

Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats

STUDY ON THE MECHANISM OF CARDIAC HYPERTROPHY INDUCED BY TESTOSTERONE THROUGH MTORC2 IN OVARIECTOMIZED FEMALE SPONTANEOUSLY HYPERTENSIVE RATS

Abstract 4129520: the Mechanism of Cardiac Hypertrophy Induced by Testosterone in Postmenopausal Women Through the Activation of the Mtorc2/atg9a

Oestradiol Supplement Minimises Coronary Occlusion-Induced Myocardial Infarction and Ventricular Dysfunction in Oophorectomised Female Rats.

Early Estrogen Replacement Therapy Attenuates Cardiac Dysfunction Caused by Aging and Ovariectomy in Female Wistar Rats

Endothelial Dysfunction and Enhanced Contractility in Microvessels from Ovariectomized Rats Roles of Oxidative Stress and Perivascular Adipose Tissue

AMPK and Estrogen‐dependent mechanisms underlying hypersensitivity to Cardiovascular Disease during menopause

The Changes of Cardiac Structure and Myocardial Cell in Ovariectomized Rats

Natural aging and ovariectomy induces parallel phosphoproteomic alterations in skeletal muscle of female mice

Effect of 17β‐oestradiol Replacement on Vascular Responsiveness in Ovariectomized Diabetic Rats